 COPENHAGEN, Denmark, July 07, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 12a data on EVX-01 and EVX-02 on Thursday, July 8, 2021. 